A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients with genetically ascertained ULD [Unverricht-Lundborg disease]

Trial Profile

A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patients with genetically ascertained ULD [Unverricht-Lundborg disease]

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Brivaracetam (Primary)
  • Indications Unverricht-Lundborg syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors UCB
  • Most Recent Events

    • 15 Dec 2015 Results from this and other trial (see profile 29358) published in the Epilepsia
    • 18 Aug 2009 Actual patient number (56) added as reported by ClinicalTrials.gov.
    • 07 Feb 2008 Status changed from in progress to completed according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top